Even genuine pens with foreign prescriptions are seized. Lawmakers and a regulatory official now want a review, as Mounjaro costs over three times more in Korea than Japan.
Recap by typeshit. Full story at Korea JoongAng Daily.
Law360 reports the European patent court could limit the use of divisional patents in a fight involving Novo Nordisk and Ozempic.
Novo had asked the court to halt Lilly advertising it objected to. The judge ruled against the request on October 26, Reuters reports.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
Judge Zahid Quraishi found Novo failed to show irreparable harm, so Lilly's superiority ads stay up while the false advertising suit continues.
Peptide talk is everywhere from YouTube to Reddit. CNBC looks at what is actually known about their safety.
Medicare open enrollment has started, and plan changes include newly negotiated drug prices and lower costs on some medications.
Loading…